In solid tumours, PD-1 efficacy is grounded in the activation of TME CD8+ T-cells via MHC-I molecules while in cHL, the alternate mechanism through MHC-II-mediated antigen presentation to CD4+ effector cells could be involved. The gene discussed is CD4; the disease is classic Hodgkin lymphoma.